Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome
Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to test the efficacy of a 20 week multi-modal treatment comprised
of lovastatin or placebo, and the Parent-implemented Language Intervention (PILI) in children
with fragile X syndrome (FXS). Children will be randomized to drug or placebo in a
double-blind design with all participating in the PILI. The primary endpoint will be to
measure improvements in spoken language and behavior among lovastatin-treated than placebo
treated participants.
Phase:
Phase 4
Details
Lead Sponsor:
Randi J. Hagerman, MD University of California, Davis